1
|
Agunbiade K, Fonville L, McGonigle J, Elliott R, Ersche KD, Flechais R, Orban C, Murphy A, Smith DG, Suckling J, Taylor EM, Deakin B, Robbins TW, Nutt DJ, Lingford‐Hughes AR, Paterson LM, Nutt D, Lingford‐Hughes A, Paterson L, McGonigle J, Flechais R, Orban C, Deakin B, Elliott R, Murphy A, Taylor E, Robbins T, Ersche K, Suckling J, Smith D, Reed L, Passetti F, Faravelli L, Erritzoe D, Mick I, Kalk N, Waldman A, Nestor L, Kuchibatla S, Boyapati V, Metastasio A, Faluyi Y, Fernandez‐Egea E, Abbott S, Sahakian B, Voon V, Rabiner I. Alterations in white matter microstructure in alcohol and alcohol‐polydrug dependence: Associations with lifetime alcohol and nicotine exposure. Addict Biol 2022. [PMCID: PMC9540248 DOI: 10.1111/adb.13207] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Evidence suggests that alcohol dependence (AD) is associated with microstructural deficits in white matter, but the relationship with lifetime alcohol exposure and the impact of polydrug dependence is not well understood. Using diffusion tensor magnetic resonance (MR) imaging, we examined white matter microstructure in relation to alcohol and polydrug dependence using data from the Imperial College Cambridge Manchester (ICCAM) platform study. Tract‐based spatial statistics were used to examine fractional anisotropy (FA) in a cohort of abstinent AD participants, most of whom had a lifetime history of dependence to nicotine. A further subgroup also had a lifetime history of dependence to cocaine and/or opiates. Individuals with AD had lower FA throughout the corpus callosum, and negative associations with alcohol and nicotine exposure were found. A group‐by‐age interaction effect was found showing greater reductions with age in the alcohol‐dependent group within corpus callosum, overlapping with the group difference. We found no evidence of recovery with abstinence. A comparison of alcohol‐only‐ and alcohol‐polydrug‐dependent groups found no differences in FA. Overall, our findings show that AD is associated with lower FA and suggest that these alterations are primarily driven by lifetime alcohol consumption and cigarette smoking, showing no relationship with exposure to other substances such as cocaine, opiates or cannabis. Reductions in FA across the adult lifespan are more pronounced in AD and offer further support for the notion of accelerated ageing in relation to alcohol dependence. These findings highlight there may be lasting structural differences in white matter in alcohol dependence, despite continued abstinence.
Collapse
Affiliation(s)
- Kofoworola Agunbiade
- Division of Psychiatry, Department of Brain Sciences Imperial College London London UK
| | - Leon Fonville
- Division of Psychiatry, Department of Brain Sciences Imperial College London London UK
| | - John McGonigle
- Division of Psychiatry, Department of Brain Sciences Imperial College London London UK
| | - Rebecca Elliott
- Neuroscience and Psychiatry Unit, Institute of Brain, Behaviour and Mental Health University of Manchester Manchester UK
| | - Karen D. Ersche
- Behavioural and Clinical Neuroscience Institute University of Cambridge Cambridge UK
- Department of Psychiatry University of Cambridge Cambridge UK
- Department of Systems Neuroscience University Medical Centre Hamburg‐Eppendorf Hamburg Germany
| | - Remy Flechais
- Division of Psychiatry, Department of Brain Sciences Imperial College London London UK
| | - Csaba Orban
- Division of Psychiatry, Department of Brain Sciences Imperial College London London UK
| | - Anna Murphy
- Neuroscience and Psychiatry Unit, Institute of Brain, Behaviour and Mental Health University of Manchester Manchester UK
| | - Dana G. Smith
- Behavioural and Clinical Neuroscience Institute University of Cambridge Cambridge UK
- Department of Psychology University of Cambridge Cambridge UK
| | - John Suckling
- Behavioural and Clinical Neuroscience Institute University of Cambridge Cambridge UK
- Department of Psychiatry University of Cambridge Cambridge UK
| | - Eleanor M. Taylor
- Neuroscience and Psychiatry Unit, Institute of Brain, Behaviour and Mental Health University of Manchester Manchester UK
| | - Bill Deakin
- Neuroscience and Psychiatry Unit, Institute of Brain, Behaviour and Mental Health University of Manchester Manchester UK
| | - Trevor W. Robbins
- Behavioural and Clinical Neuroscience Institute University of Cambridge Cambridge UK
- Department of Psychology University of Cambridge Cambridge UK
| | - David J. Nutt
- Division of Psychiatry, Department of Brain Sciences Imperial College London London UK
| | | | - Louise M. Paterson
- Division of Psychiatry, Department of Brain Sciences Imperial College London London UK
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
2
|
Orban C, McGonigle J, Flechais RS, Paterson LM, Elliott R, Erritzoe D, Ersche KD, Murphy A, Nestor LJ, Passetti F, Reed LJ, Ribeiro AS, Smith DG, Suckling J, Taylor EM, Waldman AD, Wing VC, Deakin JW, Robbins TW, Nutt DJ, Lingford‐Hughes AR, Nutt D, Lingford‐Hughes A, Paterson L, McGonigle J, Flechais R, Orban C, Deakin B, Elliott R, Murphy A, Taylor E, Robbins T, Ersche K, Suckling J, Smith D, Reed L, Passetti F, Faravelli L, Erritzoe D, Mick I, Kalk N, Waldman A, Nestor L, Kuchibatla S, Boyapati V, Metastasio A, Faluyi Y, Fernandez‐Egea E, Abbott S, Sahakian B, Voon V, Rabiner I. Chronic alcohol exposure differentially modulates structural and functional properties of amygdala: A cross‐sectional study. Addict Biol 2020. [DOI: 10.1111/adb.12980] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Affiliation(s)
- Csaba Orban
- Neuropsychopharmacology Unit, Centre for Psychiatry, Division of Brain Sciences Imperial College London London UK
- Centre for Sleep and Cognition National University of Singapore Singapore
- N.1 Institute for Health, ECE & CIRC National University of Singapore Singapore
| | - John McGonigle
- Neuropsychopharmacology Unit, Centre for Psychiatry, Division of Brain Sciences Imperial College London London UK
| | - Remy S.A. Flechais
- Neuropsychopharmacology Unit, Centre for Psychiatry, Division of Brain Sciences Imperial College London London UK
| | - Louise M. Paterson
- Neuropsychopharmacology Unit, Centre for Psychiatry, Division of Brain Sciences Imperial College London London UK
| | - Rebecca Elliott
- Neuroscience and Psychiatry Unit, Institute of Brain, Behaviour and Mental Health The University of Manchester Manchester UK
| | - David Erritzoe
- Neuropsychopharmacology Unit, Centre for Psychiatry, Division of Brain Sciences Imperial College London London UK
| | - Karen D. Ersche
- Behavioural and Clinical Neuroscience Institute University of Cambridge Cambridge UK
- Department of Psychiatry University of Cambridge Cambridge UK
| | - Anna Murphy
- Neuroscience and Psychiatry Unit, Institute of Brain, Behaviour and Mental Health The University of Manchester Manchester UK
| | - Liam J. Nestor
- Neuropsychopharmacology Unit, Centre for Psychiatry, Division of Brain Sciences Imperial College London London UK
- Department of Psychiatry University of Cambridge Cambridge UK
| | - Filippo Passetti
- Neuropsychopharmacology Unit, Centre for Psychiatry, Division of Brain Sciences Imperial College London London UK
- Behavioural and Clinical Neuroscience Institute University of Cambridge Cambridge UK
- Department of Psychiatry University of Cambridge Cambridge UK
| | - Laurence J. Reed
- Neuropsychopharmacology Unit, Centre for Psychiatry, Division of Brain Sciences Imperial College London London UK
| | - Andre S. Ribeiro
- Neuropsychopharmacology Unit, Centre for Psychiatry, Division of Brain Sciences Imperial College London London UK
| | - Dana G. Smith
- Behavioural and Clinical Neuroscience Institute University of Cambridge Cambridge UK
- Department of Psychology University of Cambridge Cambridge UK
| | - John Suckling
- Behavioural and Clinical Neuroscience Institute University of Cambridge Cambridge UK
- Department of Psychiatry University of Cambridge Cambridge UK
- Cambridgeshire and Peterborough NHS Foundation Trust Cambridgeshire UK
| | - Eleanor M. Taylor
- Neuroscience and Psychiatry Unit, Institute of Brain, Behaviour and Mental Health The University of Manchester Manchester UK
| | - Adam D. Waldman
- Centre for Neuroinflammation and Neurodegeneration Imperial College London London UK
| | - Victoria C. Wing
- Neuropsychopharmacology Unit, Centre for Psychiatry, Division of Brain Sciences Imperial College London London UK
| | - J.F. William Deakin
- Neuroscience and Psychiatry Unit, Institute of Brain, Behaviour and Mental Health The University of Manchester Manchester UK
| | - Trevor W. Robbins
- Behavioural and Clinical Neuroscience Institute University of Cambridge Cambridge UK
- Department of Psychology University of Cambridge Cambridge UK
| | - David J. Nutt
- Neuropsychopharmacology Unit, Centre for Psychiatry, Division of Brain Sciences Imperial College London London UK
| | - Anne R. Lingford‐Hughes
- Neuropsychopharmacology Unit, Centre for Psychiatry, Division of Brain Sciences Imperial College London London UK
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Murphy A, Nestor LJ, McGonigle J, Paterson L, Boyapati V, Ersche KD, Flechais R, Kuchibatla S, Metastasio A, Orban C, Passetti F, Reed L, Smith D, Suckling J, Taylor E, Robbins TW, Lingford-Hughes A, Nutt DJ, Deakin JFW, Elliott R. Acute D3 Antagonist GSK598809 Selectively Enhances Neural Response During Monetary Reward Anticipation in Drug and Alcohol Dependence. Neuropsychopharmacology 2017; 42:1925-1926. [PMID: 28701746 PMCID: PMC5520792 DOI: 10.1038/npp.2017.99] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
This corrects the article DOI: 10.1038/npp.2016.289.
Collapse
|
4
|
Murphy A, Nestor LJ, McGonigle J, Paterson L, Boyapati V, Ersche KD, Flechais R, Kuchibatla S, Metastasio A, Orban C, Passetti F, Reed L, Smith D, Suckling J, Taylor E, Obbins TWR, Lingford-Hughes A, Nutt DJ, Deakin JFW, Elliott R. Acute D3 Antagonist GSK598809 Selectively Enhances Neural Response During Monetary Reward Anticipation in Drug and Alcohol Dependence. Neuropsychopharmacology 2017; 42:1559. [PMID: 28496172 PMCID: PMC5436126 DOI: 10.1038/npp.2017.47] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
5
|
Murphy A, Nestor LJ, McGonigle J, Paterson L, Boyapati V, Ersche KD, Flechais R, Kuchibatla S, Metastasio A, Orban C, Passetti F, Reed L, Smith D, Suckling J, Taylor E, Robbins TW, Lingford-Hughes A, Nutt DJ, Deakin JFW, Elliott R. Acute D3 Antagonist GSK598809 Selectively Enhances Neural Response During Monetary Reward Anticipation in Drug and Alcohol Dependence. Neuropsychopharmacology 2017; 42:1049-1057. [PMID: 28042871 PMCID: PMC5423526 DOI: 10.1038/npp.2016.289] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/18/2016] [Revised: 12/09/2016] [Accepted: 12/19/2016] [Indexed: 01/16/2023]
Abstract
Evidence suggests that disturbances in neurobiological mechanisms of reward and inhibitory control maintain addiction and provoke relapse during abstinence. Abnormalities within the dopamine system may contribute to these disturbances and pharmacologically targeting the D3 dopamine receptor (DRD3) is therefore of significant clinical interest. We used functional magnetic resonance imaging to investigate the acute effects of the DRD3 antagonist GSK598809 on anticipatory reward processing, using the monetary incentive delay task (MIDT), and response inhibition using the Go/No-Go task (GNGT). A double-blind, placebo-controlled, crossover design approach was used in abstinent alcohol dependent, abstinent poly-drug dependent and healthy control volunteers. For the MIDT, there was evidence of blunted ventral striatal response to reward in the poly-drug-dependent group under placebo. GSK598809 normalized ventral striatal reward response and enhanced response in the DRD3-rich regions of the ventral pallidum and substantia nigra. Exploratory investigations suggested that the effects of GSK598809 were mainly driven by those with primary dependence on alcohol but not on opiates. Taken together, these findings suggest that GSK598809 may remediate reward deficits in substance dependence. For the GNGT, enhanced response in the inferior frontal cortex of the poly-drug group was found. However, there were no effects of GSK598809 on the neural network underlying response inhibition nor were there any behavioral drug effects on response inhibition. GSK598809 modulated the neural network underlying reward anticipation but not response inhibition, suggesting that DRD3 antagonists may restore reward deficits in addiction.
Collapse
Affiliation(s)
- Anna Murphy
- Neuroscience and Psychiatry Unit, University of Manchester, Manchester, UK
| | - Liam J Nestor
- Centre for Neuropsychopharmacology, Division of Brain Sciences, Imperial College London, London, UK
- Department of Psychiatry, University of Cambridge, Cambridge, UK
| | - John McGonigle
- Centre for Neuropsychopharmacology, Division of Brain Sciences, Imperial College London, London, UK
| | - Louise Paterson
- Centre for Neuropsychopharmacology, Division of Brain Sciences, Imperial College London, London, UK
| | | | - Karen D Ersche
- Department of Psychiatry, University of Cambridge, Cambridge, UK
- Department of Psychology, University of Cambridge, Cambridge, UK
| | - Remy Flechais
- Centre for Neuropsychopharmacology, Division of Brain Sciences, Imperial College London, London, UK
| | - Shankar Kuchibatla
- Neuroscience and Psychiatry Unit, University of Manchester, Manchester, UK
| | - Antonio Metastasio
- Neuroscience and Psychiatry Unit, University of Manchester, Manchester, UK
| | - Csaba Orban
- Centre for Neuropsychopharmacology, Division of Brain Sciences, Imperial College London, London, UK
| | - Filippo Passetti
- Centre for Neuropsychopharmacology, Division of Brain Sciences, Imperial College London, London, UK
| | - Laurence Reed
- Centre for Neuropsychopharmacology, Division of Brain Sciences, Imperial College London, London, UK
| | - Dana Smith
- Department of Psychiatry, University of Cambridge, Cambridge, UK
- Department of Psychology, University of Cambridge, Cambridge, UK
| | - John Suckling
- Department of Psychiatry, University of Cambridge, Cambridge, UK
| | - Eleanor Taylor
- Neuroscience and Psychiatry Unit, University of Manchester, Manchester, UK
| | - Trevor W Robbins
- Department of Psychiatry, University of Cambridge, Cambridge, UK
- Department of Psychology, University of Cambridge, Cambridge, UK
| | - Anne Lingford-Hughes
- Centre for Neuropsychopharmacology, Division of Brain Sciences, Imperial College London, London, UK
| | - David J Nutt
- Centre for Neuropsychopharmacology, Division of Brain Sciences, Imperial College London, London, UK
| | - John FW Deakin
- Neuroscience and Psychiatry Unit, University of Manchester, Manchester, UK
| | - Rebecca Elliott
- Neuroscience and Psychiatry Unit, University of Manchester, Manchester, UK
| | - ICCAM Platform
- Neuroscience and Psychiatry Unit, University of Manchester, Manchester, UK
- Centre for Neuropsychopharmacology, Division of Brain Sciences, Imperial College London, London, UK
- Department of Psychiatry, University of Cambridge, Cambridge, UK
- Department of Psychology, University of Cambridge, Cambridge, UK
| |
Collapse
|
6
|
Paterson LM, Flechais RSA, Murphy A, Reed LJ, Abbott S, Boyapati V, Elliott R, Erritzoe D, Ersche KD, Faluyi Y, Faravelli L, Fernandez-Egea E, Kalk NJ, Kuchibatla SS, McGonigle J, Metastasio A, Mick I, Nestor L, Orban C, Passetti F, Rabiner EA, Smith DG, Suckling J, Tait R, Taylor EM, Waldman AD, Robbins TW, Deakin JFW, Nutt DJ, Lingford-Hughes AR. The Imperial College Cambridge Manchester (ICCAM) platform study: An experimental medicine platform for evaluating new drugs for relapse prevention in addiction. Part A: Study description. J Psychopharmacol 2015; 29:943-60. [PMID: 26246443 DOI: 10.1177/0269881115596155] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Drug and alcohol dependence are global problems with substantial societal costs. There are few treatments for relapse prevention and therefore a pressing need for further study of brain mechanisms underpinning relapse circuitry. The Imperial College Cambridge Manchester (ICCAM) platform study is an experimental medicine approach to this problem: using functional magnetic resonance imaging (fMRI) techniques and selective pharmacological tools, it aims to explore the neuropharmacology of putative relapse pathways in cocaine, alcohol, opiate dependent, and healthy individuals to inform future drug development. Addiction studies typically involve small samples because of recruitment difficulties and attrition. We established the platform in three centres to assess the feasibility of a multisite approach to address these issues. Pharmacological modulation of reward, impulsivity and emotional reactivity were investigated in a monetary incentive delay task, an inhibitory control task, and an evocative images task, using selective antagonists for µ-opioid, dopamine D3 receptor (DRD3) and neurokinin 1 (NK1) receptors (naltrexone, GSK598809, vofopitant/aprepitant), in a placebo-controlled, randomised, crossover design. In two years, 609 scans were performed, with 155 individuals scanned at baseline. Attrition was low and the majority of individuals were sufficiently motivated to complete all five sessions (n=87). We describe herein the study design, main aims, recruitment numbers, sample characteristics, and explain the test hypotheses and anticipated study outputs.
Collapse
Affiliation(s)
- Louise M Paterson
- Centre for Neuropsychopharmacology, Imperial College London, London, UK
| | - Remy S A Flechais
- Centre for Neuropsychopharmacology, Imperial College London, London, UK
| | - Anna Murphy
- Neuroscience and Psychiatry Unit, University of Manchester, Manchester, UK
| | - Laurence J Reed
- Centre for Neuropsychopharmacology, Imperial College London, London, UK
| | - Sanja Abbott
- Behavioural and Clinical Neuroscience Institute, University of Cambridge, Cambridge, UK
| | | | - Rebecca Elliott
- Neuroscience and Psychiatry Unit, University of Manchester, Manchester, UK
| | - David Erritzoe
- Centre for Neuropsychopharmacology, Imperial College London, London, UK
| | - Karen D Ersche
- Behavioural and Clinical Neuroscience Institute, University of Cambridge, Cambridge, UK Department of Psychiatry, University of Cambridge, Cambridge, UK
| | - Yetunde Faluyi
- Cambridgeshire and Peterborough NHS Foundation Trust, Cambridge, UK
| | - Luca Faravelli
- Centre for Neuropsychopharmacology, Imperial College London, London, UK
| | - Emilio Fernandez-Egea
- Behavioural and Clinical Neuroscience Institute, University of Cambridge, Cambridge, UK Cambridgeshire and Peterborough NHS Foundation Trust, Cambridge, UK
| | - Nicola J Kalk
- Centre for Neuropsychopharmacology, Imperial College London, London, UK
| | | | - John McGonigle
- Centre for Neuropsychopharmacology, Imperial College London, London, UK
| | - Antonio Metastasio
- Neuroscience and Psychiatry Unit, University of Manchester, Manchester, UK 5 Boroughs Partnership NHS Foundation Trust, Warrington, UK
| | - Inge Mick
- Centre for Neuropsychopharmacology, Imperial College London, London, UK
| | - Liam Nestor
- Centre for Neuropsychopharmacology, Imperial College London, London, UK Clinical Research Unit, GlaxoSmithKline, Cambridge, UK
| | - Csaba Orban
- Centre for Neuropsychopharmacology, Imperial College London, London, UK
| | - Filippo Passetti
- Centre for Neuropsychopharmacology, Imperial College London, London, UK Behavioural and Clinical Neuroscience Institute, University of Cambridge, Cambridge, UK Department of Psychiatry, University of Cambridge, Cambridge, UK
| | | | - Dana G Smith
- Behavioural and Clinical Neuroscience Institute, University of Cambridge, Cambridge, UK Department of Psychology, University of Cambridge, Cambridge, UK
| | - John Suckling
- Behavioural and Clinical Neuroscience Institute, University of Cambridge, Cambridge, UK Cambridgeshire and Peterborough NHS Foundation Trust, Cambridge, UK
| | - Roger Tait
- Behavioural and Clinical Neuroscience Institute, University of Cambridge, Cambridge, UK
| | - Eleanor M Taylor
- Neuroscience and Psychiatry Unit, University of Manchester, Manchester, UK
| | - Adam D Waldman
- Centre for Neuroinflammation and Neurodegeneration, Imperial College London, London, UK
| | - Trevor W Robbins
- Behavioural and Clinical Neuroscience Institute, University of Cambridge, Cambridge, UK Department of Psychology, University of Cambridge, Cambridge, UK
| | - J F William Deakin
- Neuroscience and Psychiatry Unit, University of Manchester, Manchester, UK
| | - David J Nutt
- Centre for Neuropsychopharmacology, Imperial College London, London, UK
| | | | | |
Collapse
|
7
|
Gokaslan ZL, Chintala SK, York JE, Boyapati V, Jasti S, Sawaya R, Fuller G, Wildrick DM, Nicolson GL, Rao JS. Expression and role of matrix metalloproteinases MMP-2 and MMP-9 in human spinal column tumors. Clin Exp Metastasis 1998; 16:721-8. [PMID: 10211985 DOI: 10.1023/a:1006580728338] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Matrix metalloproteinases (MMPs) have been implicated in the process of tumor invasion and metastasis formation. Thus, we determined the expression of MMPs in various primary and metastatic spinal tumors in order to assess the role of these enzymes in spinal invasion. MMP expression was examined by immunohistochemical localization, and quantitative evaluation of MMP protein content was determined by enzyme-linked immunosorbant assay (ELISA) and Western blotting. MMP enzyme activity was determined by gelatin zymography. Lung carcinomas and melanomas metastatic to the spine were shown to have higher levels of MMP-9 activity than those of breast, thyroid, renal metastases and primary spinal tumors. Immunohistochemical analysis revealed similar difference in expression of MMP-9 in tissue samples. When the tissue samples were subjected to gelatin zymography for examination of MMP-2 and MMP-9 activity and to ELISA and Western blotting for quantitative estimation of protein content, the most striking results were obtained for lung carcinomas and melanomas relative to the other tumors. Lung carcinomas and melanomas metastatic to the spine had considerably higher levels of MMP-9 activity than those of primary spinal tumor or breast, thyroid, and renal carcinoma metastases. Within the metastatic tumor category, neoplasms that are known to be associated with the shortest overall survival rates and most aggressive behavior, such as lung carcinomas and melanomas, had the highest levels of MMP-2 and MMP-9 activity compared to those less aggressive metastatic tumors such as breast, renal cell, and thyroid carcinomas. Our results suggest that MMPs may contribute to the metastases to the spinal column, and overexpression of these enzymes may correlate with enhanced invasive properties of both primary and metastatic spinal tumors.
Collapse
Affiliation(s)
- Z L Gokaslan
- Department of Neurosurgery, The University of Texas M. D. Anderson Cancer Center, Houston 77030, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Gokaslan ZL, Chintala SK, York JE, Boyapati V, Jasti S, Sawaya R, Fuller G, Wildrick DM, Nicolson GL, Rao JS. Expression and localization of urokinase-type plasminogen activator in human spinal column tumors. Clin Exp Metastasis 1998; 16:713-9. [PMID: 10211984 DOI: 10.1023/a:1006528711499] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
We have sought to determine the production and activity of serine proteases in primary and metastatic spinal tumors and the association of these enzymes with the invasive and metastatic properties of spinal column tumors. Using immunohistochemical techniques, the cellular localization and expression of urokinase-type plasminogen activator (uPA) was assessed, whereas its activity was determined by fibrin zymography, and the amounts of enzyme were measured by an enzyme-linked immunosorbent assay (ELISA) in primary spinal column tumors (chordoma, chondrosarcoma, and giant cell tumor) and metastatic tumors of the spine arising from various malignancies (breast, lung, thyroid, and renal cell carcinomas, and melanomas). Metastatic tumors displayed higher levels of uPA activity than did primary spinal tumors (P<0.001). Immunohistochemical analysis revealed that uPA expression was highest in metastases from lung and breast carcinomas and melanomas, followed by metastatic tumors from thyroid and renal cell carcinomas. Similar results were obtained for uPA activity and enzyme level as determined by fibrin zymography and ELISA, respectively. We conclude that metastatic spinal tumors possess higher levels of uPA expression and activity than the primary spinal tumors, which tend to be less aggressive and only locally invasive malignancies. The results suggest that the plasminogen system may participate in the metastasis of tumors to the spinal column.
Collapse
Affiliation(s)
- Z L Gokaslan
- Department of Neurosurgery, The University of Texas M. D. Anderson Cancer Center, Houston 77030, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|